S&P 500
7,507.70
+0.74%
Dow Jones
52,457.00
+0.31%
Nasdaq 100
30,279.60
+1.61%
Russell 2000
3,020.07
+0.36%
FTSE 100
10,513.20
-0.26%
Nikkei 225
71,242.30
+0.83%
Live Nasdaq Composite: Markets Take Breather After Impressive Q2 Showing on Easing Oil Outlook

Health and Healthcare

Is Merck Overpaying for Immune Design?

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Is Merck Overpaying for Immune Design?

© solvod / iStock

Immune Design Corp. (NASDAQ: IMDZ) shares absolutely exploded on Thursday after Merck & Co. Inc. (NYSE: MRK | MRK Price Prediction) announced that it would be acquiring the firm at what some might call a ridiculous premium.

Under the terms of the agreement, Merck will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million. Although this is an incredible premium for Immune Design, it is just a drop in the buck for Merck, which boasts a market cap of roughly $206 billion.

It’s worth pointing out that, Immune Design shares were only up about 9% so far year to date, and over the past 52 weeks the stock was down over 57%.

Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s proprietary technologies, GLAAS and ZVex, are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases.

[nativounit]

The transaction is expected to close early in the second quarter of 2019.

Dr. Roger M. Perlmutter, president of Merck Research Laboratories, commented:

Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development. This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.

Shares of Immune Design were last seen up about 309% at $5.81 early Thursday, in a 52-week range of $1.10 to $5.82. The stock has a consensus price target of $4.13.

Merck traded at $79.25 a share. The 52-week range is $52.83 to $80.19 and the consensus price target is $82.81.

[recirclink id=529641]

[wallst_email_signup]

Contact [email protected] for any questions or corrections.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here's the Cliff.
Drew Wood |

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here's the Cliff.
The 11-Year Tax Window Most Retirees Miss Between 62 and 73
David Beren |

The 11-Year Tax Window Most Retirees Miss Between 62 and 73

Continue Reading

cgblaine22 |

Peregrine Move Looks Sustainable, at Least for Now

Peregrine Pharmaceuticals may be on the verge of something big with its anticancer drugs. The shares soared almost 50% on…

Jon C. Ogg |

What This Skin Cancer Drug Approval Really Means to Merck

Merck & Co. has received approval from the FDA to bring its new drug Keytruda to market.

What Sanofi Is Adding to Its Portfolio With This New Acquisition
Chris Lange |

What Sanofi Is Adding to Its Portfolio With This New Acquisition

Principia Biopharma shares jumped to start out the week after it was announced that it would be acquired by Sanofi.

High Hopes and Expectations for Merck’s First Investor Day in Years
Jon C. Ogg |

High Hopes and Expectations for Merck’s First Investor Day in Years

Merck is set to host its Investor Day on June 20. Investors will have a high bar of expectations because…

Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% or More Upside Potential
Lee Jackson |

Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% or More Upside Potential

These five Goldman Sachs picks trading under the $10 level that could provide investors with some incredible upside potential. Odds…

Trey Thoelcke |

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not…

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO
Chris Lange |

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Here is why Genocea Biosciences is one of the big winners from the annual meeting of the American Society of…

David J. Phillips |

Dendreon Buyout, How Imminent?

Though near-term growth visibility for its cancer vaccine Provenge remains cloudy, Seattle-based Dendreon (DNDN) could be an attractive takeover candidate…

SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now
Lee Jackson |

SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now

Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less…

Top Gaining Stocks

Axon Enterprise
AXON • Vol: 645,307
Air Products & Chemicals
APD • Vol: 1,308,953
AMD
AMD • Vol: 15,290,671
Intel
INTC • Vol: 52,828,193
KLA
KLAC • Vol: 6,023,282

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Zimmer Biomet
ZBH • Vol: 1,686,458
Stryker
SYK • Vol: 1,021,548
Mosaic
MOS • Vol: 7,437,514
Digital Realty Trust
DLR • Vol: 5,070,561